Chimeric Therapeutics Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- $8.4 M funding to drive CHM CDH17 and resignation of CMO
- Trading Halt
- CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
- Chimeric receives $4.5M R&D tax incentive
- 75% disease control observed in CHM CDH17 trial
Later from Chimeric Therapeutics
- Funding and EGM update
- Portfolio streamlined - return of CHM CLTX to City of Hope
- Half Year Report and Appendix 4D 31 December 2025
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
- Consolidation/Split - CHM
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics